Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Current Assets (2016 - 2025)

Historic Current Assets for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $176.9 million.

  • Editas Medicine's Current Assets fell 3476.0% to $176.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.9 million, marking a year-over-year decrease of 3476.0%. This contributed to the annual value of $289.3 million for FY2024, which is 1511.43% down from last year.
  • Per Editas Medicine's latest filing, its Current Assets stood at $176.9 million for Q3 2025, which was down 3476.0% from $182.8 million recorded in Q2 2025.
  • Editas Medicine's 5-year Current Assets high stood at $632.3 million for Q1 2021, and its period low was $176.9 million during Q3 2025.
  • In the last 5 years, Editas Medicine's Current Assets had a median value of $356.8 million in 2022 and averaged $382.5 million.
  • As far as peak fluctuations go, Editas Medicine's Current Assets skyrocketed by 4874.31% in 2021, and later crashed by 3616.43% in 2025.
  • Quarter analysis of 5 years shows Editas Medicine's Current Assets stood at $507.3 million in 2021, then decreased by 29.68% to $356.8 million in 2022, then fell by 4.46% to $340.8 million in 2023, then dropped by 15.11% to $289.3 million in 2024, then crashed by 38.86% to $176.9 million in 2025.
  • Its last three reported values are $176.9 million in Q3 2025, $182.8 million for Q2 2025, and $224.8 million during Q1 2025.